Researchers reveal 3D structure responsible for gene expression
Researchers have produced the first 3D image of the Mediator-bound pre-initiation complex, key in the regulation of gene expression.
List view / Grid view
Researchers have produced the first 3D image of the Mediator-bound pre-initiation complex, key in the regulation of gene expression.
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
A team has discovered how enzymes control the formation of bioactive rubromycin-polyketides, which could be used to bioengineer new compounds.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
Researchers have developed a new technique called mim-tRNAseq to measure, map and analyse tRNAs in cells, providing insight into disease.
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
A high-throughput screening assay for macrocyclic peptides with affinity to ubiquitin has been created by researchers.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
Researchers have developed a personalised medicine platform that could advance genomic medicine research for cancer.
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.